Quick Answer
Ovid Therapeutics Inc. reported Stockholders Equity of $130.66 million for fiscal year 2025.
Ovid Therapeutics Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $130.66M | +91.5% |
| 2024 | $68.23M | -22.3% |
| 2023 | $87.80M | -33.6% |
| 2022 | $132.27M | -26.4% |
| 2021 | $179.75M | +312.0% |
| 2020 | $43.63M | -37.7% |
| 2019 | $70.02M | +80.4% |
| 2018 | $38.81M | -53.5% |
| 2017 | $83.44M | +69.3% |
| 2016 | $49.29M | -27.6% |
| 2015 | $68.07M | +1336.6% |
| 2014 | $4.74M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $44.70M | -41.4% | -19.9% |
| June 30, 2025 | $55.79M | -37.2% | -5.9% |
| March 31, 2025 | $59.28M | -24.3% | -13.1% |
| December 31, 2024 | $68.23M | -22.3% | -10.6% |
| September 30, 2024 | $76.29M | -24.7% | -14.2% |
| June 30, 2024 | $88.90M | -19.7% | +13.6% |
| March 31, 2024 | $78.28M | -35.3% | -10.8% |
| December 31, 2023 | $87.80M | -33.6% | -13.3% |
- Ovid Therapeutics Inc. showed an increase of +91.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2014–2025 period, Ovid Therapeutics Inc.’s stockholders equity has grown by 2657.6% (from $4.74 million to $130.66 million).
- The most recent figure is from Ovid Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: